Patients followed within the Immuno-Allergology Service of the CHU Brugmann Hospital, who received an allergy assessment between 01/01/2015 and 31/12/2015. At least 1400 dermis will be analyzed. The allergens tested include: dermatophagoides pteronyssinus (DEPT), dermatophagoides farinae (DPF), blomia, cat, dog, cockroach, orchardgrass, timothy grass, alder, hazel,birch, olive tree, cypress, ash, latex, aspergillus, alternaria, cladosporium, peanut, hazel.

Allergy

The results of the allergen skin tests will be encoded as the edema diameter. The allergenicity score (mean of the skin reactivities for each allergen) will be compared between each age groups. The impact of tabagism, gender, BMI and residential area on the allergic reactivity will also be assessed in the overall population and within each age group.

Retrospective analysis of patient files

CHU Brugmann

Impact of Age on the Prevalence of Allergic Sensitization

Mean of the skin reactivities for each allergen. The results of the allergen skin tests are encoded as the edema diameter. Scores will be compared between the different age groups.

Effect of the smoking/non smoking status on the allergic reactivity, analysed in the hole group and in the different age groups.

Effect of the area of residence on the allergic reactivity, analysed in the hole group and in the different age groups.

Gender effect on the allergic reactivity, analysed in the hole group and in the different age groups.

Effect of the body mass index on the allergic reactivity, analysed in the hole group and in the different age groups.

Olivier Michel

Head of clinic

Brugmann University Hospital

prerseasonal course of SCIT - three years

Purethal

Purethal -placebo

Grass Pollen Subcutaneous Immunotherapy in Elderly Patients

Grass Pollen Subcutaneous Immunotherapy: a Double-blind, Placebo-controlled Study in Elderly Patients With an Allergy to Grass Pollen

The prime outcome measure was the area under the curve (AUC) for combined symptom and medication score (SMS)

Evaluation quantities of drugs based on patient diary.

The local reactions were assessed at 30 min after injection and measured in cm.

The systemic reaction were assesed after injection according EAACI criteria.

Andrzej Bozek

Andrzej Bozek Assistant Professor, Director of Research

Medical University of Silesia

2 capsules of BI 671800 ED 25 mg plus 2 capsules of BI 671800 ED placebo (bid in the morning and evening) plus 1 over-encapsulated montelukast placebo tablet (qd in the morning) plus fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)

2 capsules of BI 671800 ED 100 mg plus 2 capsules of placebo (bid in the morning and evening) plus 1 over-encapsulated montelukast placebo tablet (qd in the morning) plus fluticasone propionate nasal spray placebo (2 puffs each nostril qd in the morning)

1 over-encapsulated montelukast 10 mg tablet (qd in the morning) plus 4 capsules of BI 671800 ED placebo (bid in the morning and evening) plus fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)

Fluticasonepropionate nasal spray 200 mcg (qd, 2 puffs of 50 ¿g per nostril) plus 4 capsules of BI 671800 ED placebo (bid in the morning and evening) plus 1 overencapsulated montelukast placebo tablet (qd in the morning)

4 capsules of BI 671800 ED placebo (bid in the morning and evening), plus 1 over-encapsulated montelukast placebo tablet (qd in the morning) plus fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)

4 capsules of BI 671800 ED 100 mg (bid in the morning and evening) plus 1 over-encapsulated montelukast placebo tablet (qd in the morning) plus fluticasone propionate nasal spray placebo (2 puffs each nostril qd in the morning)

Rhinitis, Allergic, Seasonal

Asthma

BI 67100 ED 25 mg

2 capsules of BI 671800 ED placebo (bid in the morning and evening)

BI 671800 ED placebo

1 over-encapsulated montelukast placebo tablet (qd in the morning)

montelukast placebo tablet

fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)

fluticasone propionate placebo nasal spray

4 capsules of BI 671800 ED 100 mg (bid in the morning and evening)

BI 671800 ED 100 mg

4 capsules of BI 671800 ED placebo (bid in the morning and evening)

2 capsules of BI 671800 ED 100 mg (bid in the morning and evening)

671800 ED placebo

1 over-encapsulated montelukast 10 mg tablet (qd in the morning)

montelukast 10 mg tablet

fluticasone propionate nasal spray placebo (2 puffs each nostril qd in the morning)

fluticasone propionate nasal spray placebo

Fluticasonepropionate nasal spray 200 mcg (qd, 2 puffs of 50 mcg per nostril)

Fluticasonepropionate nasal spray 200 mcg

1268.41.49001 Boehringer Ingelheim Investigational Site

Randomized, Placebo Controlled, Crossover Study in an Environmental Challenge Chamber to Assess Safety & Efficacy of Three Oral Doses of BI 671800 Versus Fluticasone Propionate and Montelukast in Sensitive Seasonal Allergic Rhinitis Patients Out of Season

Randomised, Double-blind, Triple Dummy, Partial Cross-over (Each Active Treatment With Placebo) Study Using an Environmental Challenge Chamber (ECC) to Assess the Safety and Efficacy of 2 Weeks of Oral BI 671800 ED 50, 200 or 400 mg Bid, Compared to Montelukast 10 mg qd, Fluticasone Propionate Nasal Spray 200 µg qd (2 Nasal Actuations Each Nostril of 50 µg) Versus Placebo in Seasonal Allergic Rhinitis Patients Out of Season, Sensitive to Dactylis Glomerata.

dactylis glomerata/hypersensitivity

Impact of Age on the Prevalence of Allergic Sensitization

Grass Pollen Subcutaneous Immunotherapy in Elderly Patients

Randomized, Placebo Controlled, Crossover Study in an Environmental Challenge Chamber to Assess Safety & Efficacy of Three Oral Doses of BI 671800 Versus Fluticasone Propionate and Montelukast in Sensitive Seasonal Allergic Rhinitis Patients Out of Season

The most complete medicinal herbs database backed by science